Albani-Campanario M, Buendía-Díaz G, Flores-Islas ML, Maquita-Nakano C, Ochoa-Cervantes J

Language: Spanish
References: 8
Page: 355-359
PDF size: 188.03 Kb.

ABSTRACT

There are several treatment options for postmenopausic patients suffering from ostopenia or osteoporosis; one of them being inhibition of bone resorption using bisphosphonates. The most common side effects of these drugs are of gastrointestinal nature. There are, of course, other side effects that could jeopardize the function and integrity of other organs or systems. A case of a 58-year-old patient presenting zoledronic-acid induced uveitis symptoms is reported. The importance of this paper lies in that this complication is rather exceptional, in particular if associated with the biphosphonate in question.

REFERENCES

1. Fraundeler F. Ocular side effects associated with bisphosphonates. DrugsToday 2003;39:829-835.

2. Dustin D, Curtis E. Posmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a National Veteran cohort. Retina 2008;28:889-893.

3. Sunyeez J, Derman R. Update on the Use of Bisphosphonates in the Management of Postmenopausal Osteoporosis by Obstetricians-Gynecologists. Obstetrical and Gynecological Survey 2007;62:407-416.

4. Favus, Murray J. Bisphosphonates for Osteoporosis. The New England Journal of Medicine 2010;363:2027-2035.

5. Coleman R. Risk and benefits of bisphosphonates. British Journal of Cancer 2008;98:1736-1740.

6. Black D, Delmas P, Eastell R, et al. For the HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822.

7. Benderson D, Karakurnnel J, Kathuria S. Scleritis complicating zolendronic acid infusion. Clinical Lymphoma & Myeloma 2006;7:145-147.

8. Tay Kearney ML, Schwam BL, Lowder C, et al. Clinical features and associated systemic diseases of HLA-B27 uveitis. Am J Ophthalmol 1996;121:47-56.